Comparison of Cytotoxic Activity of L778123 as a Farnesyltranferase Inhibitor and Doxorubicin against A549 and HT-29 Cell Lines
Purpose: Farnesyltransferase (FTase) is a zinc-dependent enzyme that adds a farnesyl group to the Ras proteins. L778, 123 is a potent peptidomimetic imidazole-containing FTase inhibitor. Methods: L778123 was synthesized according to known methods and evaluated alone and in combination with doxorubic...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Book |
| Published: |
Tabriz University of Medical Sciences,
2013-02-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_8bb975bed40f489980a527d8799a1ca1 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a Ali Abdollahi |e author |
| 700 | 1 | 0 | |a Davoud Asgari |e author |
| 700 | 1 | 0 | |a Simin Sharifi |e author |
| 700 | 1 | 0 | |a Soodabeh Davaran |e author |
| 700 | 1 | 0 | |a Saeed Ghasemi |e author |
| 700 | 1 | 0 | |a Javid Shahbazi Mojarrad |e author |
| 245 | 0 | 0 | |a Comparison of Cytotoxic Activity of L778123 as a Farnesyltranferase Inhibitor and Doxorubicin against A549 and HT-29 Cell Lines |
| 260 | |b Tabriz University of Medical Sciences, |c 2013-02-01T00:00:00Z. | ||
| 500 | |a 10.5681/apb.2013.012 | ||
| 500 | |a 2228-5881 | ||
| 500 | |a 2251-7308 | ||
| 520 | |a Purpose: Farnesyltransferase (FTase) is a zinc-dependent enzyme that adds a farnesyl group to the Ras proteins. L778, 123 is a potent peptidomimetic imidazole-containing FTase inhibitor. Methods: L778123 was synthesized according to known methods and evaluated alone and in combination with doxorubicin against A549 (adenocarcinomic human alveolar basal epithelial cells) and HT29 (human colonic adenocarcinoma) cell lines by MTT assay. Results: L778123 showed weak cytotoxic activity with IC50 of 100 and 125 for A549 and HT-29 cell lines, respectively. The combination of doxorubicin and L778123 can decrease IC50 of doxorubicin in both cell lines significantly. Conclusion: It can be concluded that L778, 123 can be a good agent for combination therapy. | ||
| 546 | |a EN | ||
| 690 | |a Farnesyltransferase inhibitor | ||
| 690 | |a MTT assay | ||
| 690 | |a Combination therapy | ||
| 690 | |a L-778123 | ||
| 690 | |a Therapeutics. Pharmacology | ||
| 690 | |a RM1-950 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Advanced Pharmaceutical Bulletin, Vol 3, Iss 1, Pp 73-77 (2013) | |
| 787 | 0 | |n http://journals.tbzmed.ac.ir/PDF/APB/Manuscript/APB-3-73.pdf | |
| 787 | 0 | |n https://doaj.org/toc/2228-5881 | |
| 787 | 0 | |n https://doaj.org/toc/2251-7308 | |
| 856 | 4 | 1 | |u https://doaj.org/article/8bb975bed40f489980a527d8799a1ca1 |z Connect to this object online. |